logo@2x
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Contact Us
  • Disease Focus
    • MYELOFIBROSIS
  • Science
    • Pipeline
    • MOMELOTINIB
    • Publications & KOL Presentations
  • Patients
    • MOMENTUM Clinical Trial
    • Expanded Access Protocol
    • Patient Resources
  • Investors
  • Careers
  • company
    • About Us
    • Leadership
    • Board of Directors
    • Careers
    • Contact us
  • Science
    • Science Overview
    • DDR
  • Development
    • Development Overview
    • SRA737
    • SRA141
  • Investors
    • Investors Overview
    • News Release
    • Events & Webcasts
    • Presentations
    • Financial Reporting
    • Quarterly Results
    • Stock Information
    • Corporate Governance
    • FAQs
    • Investor Alerts

Financial Reporting

NASDAQ: SRRANASDAQ: DNAI
YearTrailing 12-MonthsCalendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2017Calendar Year 2016Calendar Year 2015Calendar Year 2014Calendar Year 2013Calendar Year 2012Calendar Year 2010Calendar Year 2009Calendar Year 2008Calendar Year 2007Calendar Year 2006Calendar Year 2005Calendar Year 2004
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
DOfficial notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the ActApr 4, 2012Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in HTML.Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in DOC file.Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in PDF file.

Form 8937 - Reverse Split (Jan 2020)
Form 8937 - Reverse Split (Jan 2020) Common Stock Warrants
Form 8937 - Reverse Split (Jan 2020) Series A & B Warrants
Form 8937 - Stock Conversion (Jan 2020)


  • Investor Relations
  • News Releases
  • Events & Webcasts
  • Presentations
  • Publications
  • Financial Reporting
  • Stock Information
  • Corporate Governance
  • FAQs
  • Investor Alerts
logo@2x
About Us
  • Overview
  • Leadership
  • Board of Directors
  • Contact Us
Follow Us
Disease Focus
  • MYELOFIBROSIS
Science
  • Pipeline
  • MOMELOTINIB
  • Publications & KOL Presentations
Patients
  • MOMENTUM Clinical Trial
  • Expanded Access Protocol
  • Patient Resources
Follow Us
Copyright © 2005-2019 Sierra Oncology, Inc. All Rights Reserved.
  • Privacy Notice
  • Terms of Use
Copyright © 2005-2019 Sierra Oncology, Inc. All Rights Reserved.